Marie Sklodowska-Curie Actions (MSCA)
Marie Sklodowska-Curie Fellowships are European research grants available to researchers regardless of their nationality or field of research. The general objective is to stimulate the mobility of researchers.
Your NCP contact for this programme
Margot Beereboom
margot.beereboom@fwo.be
+32 2 550 15 76
About this programme
Marie Sklodowska-Curie Fellowships are European research grants available to researchers regardless of their nationality or field of research. In addition to generous research funding scientists have the possibility to gain experience abroad and in the private sector, and to complete their training with competences or disciplines useful for their careers.
The Marie Sklodowska-Curie programme aims to foster innovation, research-business cooperation and also includes a strong international component based on the principle of mobility.
The MSCA provides funding for all stages of research careers, being doctoral candidates or highly experienced researchers and by ensuring good working conditions and work/life balance for the researchers.
The programme is open to all fields of research and innovation, from fundamental research to market take-up and innovation services. Furthermore, it also encourages mobility between the different sectors (universities, research centres, and companies), disciplines and countries.
There are five types of Marie Sklodowska-Curie Actions:
- Postdoctoral Fellowships (PF)
- Doctoral Networks (DN)
- Staff Exchange (SE)
- Co-funding of regional, national and international doctoral and postdoctoral programmes (COFUND)
- MSCA and Citizens - European Researchers’ Night
Latest news
Upcoming events
Work Programme & Calls
Infosheets
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
-
No infosheets available for this domain
Related links
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
- Horizon Europe Marie Skłodowska-Curie Actions Financial Guide
- MSCA Navigating the UK Immigration Landscape – UKRI webinar presentation (December 2022)
- Work Programme MSCA 2021-2022
- MSCA GAP and UK entities - UKRI webinar presentation (September 2022) slide 24 – 29
- MSCA GAP and UK entities - UKRI webinar (September 2022) from 00:52:00 min
- MSCA matchmaking platform
- History of Changes - MSCA Work Programme 2021-2022
- EURAXESS portal: MSCA PhD and postdoc vacancies
- European Research Executive Agency HE MSCA
- Horizon Europe Unit Grants Model Grant Agreement
- MSCA Green Charter
- MSCA Guidelines on Supervision
- Factsheet MSCA under HEurope - main characteristics
- MSCA projects COVID-19
- MSCA COVID-19 portal
- EC DG Research and Innovation - MSCA
- MCAA Alumni Association
- MSCA NCP network
Documents
Documents contain additional information related to this programme, and are similar to related links.
- Results of MSCA end of fellowship evaluation questionnaires (H2020) 2024 update
- Marie Skłodowska-Curie actions – Lessons Learnt from the implementation of European Industrial Doctorates in Horizon 2020 – Report from the Cluster Event with European Industrial Doctorates (10 November 2022)
- Synergies between the MSCA and the European Institute of Innovation and Technology (EIT)
- Study on mobility flows of researchers in the context of the Marie Sklodowska-Curie Actions
- Synergies between MSCA and Erasmus+ in the higher education area
Testimonial
BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
